Review
Biochemistry & Molecular Biology
Magdalena Druszczynska, Magdalena Godkowicz, Jakub Kulesza, Sebastian Wawrocki, Marek Fol
Summary: Cytokine receptors play a critical role in regulating immune response against mycobacteria by recognizing and binding specific cytokines and activating intracellular signaling pathways. Mutations in cytokine receptor genes may lead to increased susceptibility to mycobacteria and impaired immune surveillance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Jingjing Qi, Adeline Crinier, Bertrand Escaliere, Youqiong Ye, Zhengting Wang, Tianyu Zhang, Luciana Batista, Hongzhi Liu, Liwen Hong, Ningbo Wu, Mingnan Zhang, Lei Chen, Yingbin Liu, Lei Shen, Emilie Narni-Mancinelli, Eric Vivier, Bing Su
Summary: Innate lymphoid cells (ILCs) are tissue-resident lymphocytes without antigen-specific receptors, and their roles in cancer immunity and immunotherapy are still unclear. Studies have identified tumor-specific ILC subsets in colorectal cancer (CRC) patients, with SLAMF1 potentially serving as an anti-tumor biomarker.
CELL REPORTS MEDICINE
(2021)
Article
Cell Biology
Zhenghai Tang, Dominique Davidson, Rui Li, Ming-Chao Zhong, Jin Qian, Jun Chen, Andre Veillette
Summary: The blockade of inhibitory checkpoint SIRPa-CD47 enhances phagocytosis of cancer cells by macrophages, and additional pro-phagocytic receptors, including unconventional integrins CD11a and CD11c, play a role in broadening the scope of phagocytosis, especially under inflammatory stimuli. These findings suggest that inflammatory macrophages exploit unconventional pro-phagocytic integrins for improved phagocytosis and anti-tumor immunity.
Article
Oncology
Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin
Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Mariko Ishibashi, Rimpei Morita, Hideto Tamura
Summary: Multiple myeloma is an incurable hematological malignancy characterized by abnormal plasma cells. The review focuses on the signaling lymphocytic activation molecule family receptors and their biological functions in MM, highlighting the potential of novel immunotherapies for relapse prevention.
Article
Oncology
Tineke Casneuf, Homer C. Adams, Niels W. C. J. van de Donk, Yann Abraham, Jaime Bald, Greet Vanhoof, Koen Van der Borght, Tina Smets, Brad Foulk, Karl C. Nielsen, Joshua Rusbuldt, Amy Axel, Andrew Lysaght, Hugo Ceulemans, Frederik Stevenaert, Saad Z. Usmani, Torben Plesner, Herve Avet-Loiseau, Inger Nijhof, Tuna Mutis, Jordan M. Schecter, Christopher Chiu, Nizar J. Bahlis
Summary: Daratumumab, a CD38-targeted antibody approved for MM treatment, has a novel immunomodulatory mechanism that enhances immune response and reduces NK cells. It affects T cell proportion and function, as well as reduces immunosuppressive T cells.
Review
Oncology
Liwei Sun, Xuelong Xu, Fanguang Meng, Qian Liu, Hankang Wang, Xiaodong Li, Guijie Li, Feng Chen
Summary: Lenvatinib plus TACE therapy is a favorable treatment option for patients with hepatocellular carcinoma, particularly for those who are not suitable for TACE. It has shown superior efficacy compared to monotherapy with Lenvatinib or other therapies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
S. Yusuf, P. Joseph, A. Dans, P. Gao, K. Teo, D. Xavier, P. Lopez-Jaramillo, K. Yusoff, A. Santoso, H. Gamra, S. Talukder, C. Christou, P. Girish, K. Yeates, F. Xavier, G. Dagenais, C. Rocha, T. McCready, J. Tyrwhitt, J. Bosch, P. Pais
Summary: This study showed that combined treatment with a polypill plus aspirin reduced cardiovascular events among participants without cardiovascular disease but at intermediate cardiovascular risk. However, the polypill alone or aspirin alone did not significantly reduce cardiovascular events. Participants in the polypill group had a higher incidence of hypotension or dizziness compared to the placebo group.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Clinical Neurology
Cendrine Foucard, Aurore San-Galli, Clement Tarrano, Hugo Chaumont, Annie Lannuzel, Emmanuel Roze
Summary: Neurological manifestations such as acute cerebellar ataxia and myoclonus can occur in COVID-19 patients, with early recognition and treatment leading to rapid recovery.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Cell Biology
Huaying Zhao, Yue Xu, Yilin Xie, Lan Zhang, Ming Gao, Shenglei Li, Feng Wang
Summary: This study revealed that aberrations in m6A regulators are closely associated with prognosis in esophageal cancer, with some regulators significantly correlated to disease severity and poor outcomes. The levels of m6A regulators are also related to the expression of immune regulators and immune infiltration levels in EC, suggesting their involvement in tumor progression through RNA binding and cell proliferation regulation.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Blair McNamara, Yifan Chang, Levent Mutlu, Justin Harold, Alessandro D. Santin
Summary: Despite progress in cervical cancer prevention and treatment, there is still a high global morbidity and mortality rate. Immunotherapy in combination with standard chemotherapy offers a potential additional benefit.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Multidisciplinary Sciences
P. Harraka, H. Mack, D. Colville, D. Barit, D. Langsford, T. Pianta, F. Ierino, Judy Savige
Summary: Retinal drusen are found in patients with glomerulonephritis, indicating systemic complement activation and suggesting the potential benefits of complement-targeted treatment.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Kang Chen, Wei Wei, Lei Liu, Zhu-Jian Deng, Le Li, Xiu-Mei Liang, Ping-Ping Guo, Lu-Nan Qi, Zhi-Ming Zhang, Wen-Feng Gong, Shan Huang, Wei-Ping Yuan, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong
Summary: In patients with unresectable hepatocellular carcinoma, combination therapy of lenvatinib and ICIs showed significantly improved efficacy and manageable safety compared to lenvatinib monotherapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Biochemical Research Methods
Raghvendra Mall, Mohamad Saad, Jessica Roelands, Darawan Rinchai, Khalid Kunji, Hossam Almeer, Wouter Hendrickx, Francesco M. Marincola, Michele Ceccarelli, Davide Bedognetti
Summary: An active T-helper 1/cytotoxic response in different tumors is associated with immunotherapy responsiveness and favorable prognosis. However, in some cancers, intratumoral immune activation does not prevent progression or relapse. Defining mechanisms of immune evasion is crucial for refining stratification algorithms, guiding treatment decisions, and identifying candidates for immune-targeted therapy.
BRIEFINGS IN BIOINFORMATICS
(2021)
Article
Oncology
Jiakai Hou, Yunfei Wang, Leilei Shi, Yuan Chen, Chunyu Xu, Arash Saeedi, Ke Pan, Ritu Bohat, Nicholas A. Egan, Jodi A. McKenzie, Rina M. Mbofung, Leila J. Williams, Zhenhuang Yang, Ming Sun, Xiaofang Liang, Jordi Rodon Ahnert, Navin Varadarajan, Cassian Yee, Yiwen Chen, Patrick Hwu, Weiyi Peng
Summary: This study used genome-wide CRISPR immune screens to identify immunosuppressive mechanisms in non-responders to cancer immunotherapy and integrated the results with multi-omics clinical data to evaluate the role of tumor intrinsic factors in regulating two key steps of cancer immunotherapy. Two distinct types of immune resistance regulators were revealed, with PRMT1 and RIPK1 identified as potential therapeutic targets to improve the efficacy of immunotherapy. Targeting PRMT1 and RIPK1 sensitized tumors to T-cell killing and anti-PD-1/OX40 treatment, providing novel targets for rational immuno-oncology combinations.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
